StockNews.com lowered shares of USANA Health Sciences (NYSE:USNA) from a strong-buy rating to a buy rating in a research report sent to investors on Friday morning.

USNA has been the topic of several other research reports. Zacks Investment Research cut shares of USANA Health Sciences from a strong-buy rating to a hold rating in a research report on Wednesday, December 29th. TheStreet cut shares of USANA Health Sciences from a b rating to a c+ rating in a research report on Wednesday, February 9th.

USANA Health Sciences stock opened at $88.23 on Friday. USANA Health Sciences has a 52-week low of $79.92 and a 52-week high of $107.85. The firm has a market capitalization of $1.72 billion, a price-to-earnings ratio of 13.47 and a beta of 0.85. The company has a fifty day simple moving average of $98.62 and a 200-day simple moving average of $97.47.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Monday, February 7th. The company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.28 by ($0.25). USANA Health Sciences had a net margin of 11.05% and a return on equity of 32.68%. During the same quarter last year, the firm posted $1.87 EPS. As a group, equities analysts expect that USANA Health Sciences will post 5.98 EPS for the current fiscal year.

In other USANA Health Sciences news, COO Walter Noot sold 6,193 shares of the company’s stock in a transaction dated Thursday, December 16th. The shares were sold at an average price of $102.25, for a total value of $633,234.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Daniel A. Macuga sold 368 shares of the company’s stock in a transaction dated Wednesday, December 8th. The shares were sold at an average price of $100.86, for a total transaction of $37,116.48. The disclosure for this sale can be found here. Corporate insiders own 0.21% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Reilly Financial Advisors LLC acquired a new stake in shares of USANA Health Sciences during the fourth quarter worth about $32,000. Point72 Hong Kong Ltd lifted its position in shares of USANA Health Sciences by 488.0% during the third quarter. Point72 Hong Kong Ltd now owns 488 shares of the company’s stock worth $45,000 after purchasing an additional 405 shares in the last quarter. Altshuler Shaham Ltd increased its stake in shares of USANA Health Sciences by 28.3% during the third quarter. Altshuler Shaham Ltd now owns 508 shares of the company’s stock worth $47,000 after buying an additional 112 shares during the period. Covestor Ltd purchased a new stake in shares of USANA Health Sciences during the fourth quarter worth approximately $49,000. Finally, CWM LLC purchased a new stake in shares of USANA Health Sciences during the fourth quarter worth approximately $71,000. 54.82% of the stock is currently owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, Personal Care and Skincare, and All Other. The Essentials Nutritionals category includes vitamin and mineral supplements that provide a foundation of advanced total body nutrition for every age group.

Featured Stories